File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
  • Find via Find It@HKUL
Supplementary

Conference Paper: Incidence of deferasirox-associated renal tubular dysfunction in children and young adults with beta-thalassemia

TitleIncidence of deferasirox-associated renal tubular dysfunction in children and young adults with beta-thalassemia
Authors
KeywordsPediatrics
Issue Date2014
PublisherMedcom Limited. The Journal's web site is located at http://www.hkjpaed.org/index.asp
Citation
The 2014 Joint Annual Scientific Meeting of the Hong Kong Paediatric Society and Hong Kong Paediatric Nurses Association, Hong Kong, 15 June 2014. In Hong Kong Journal of Paediatrics, 2014, v. 19 n. 3, p. 193 How to Cite?
AbstractRenal tubular dysfunction has been reported in patients on deferasirox therapy but no systematic study has been performed. This study aimed to determine the cumulative incidence of renal tubular dysfunction and serum electrolyte imbalances among children and young adults with transfusion-dependent beta-thalassaemia on deferasirox and study their intermediate term outcomes. Mean age was 15.89 years (range: 2.6-24.10 years). Nine (50.0%) patients were on deferasirox, three (16.7%) were on deferoxamine, two (11.1%) were on deferiprone, and four (22.2%) were on combination deferiprone and deferoxamine. Twelve (66.7%) patients had renal tubular dysfunction, defined by elevated urine -2 microglobulin, of whom nine were on deferasirox. Eight patients (44.4%) had concomitant serum electrolyte imbalance, all of whom were on deferasirox. Compared to those on other chelation regimens, patients on deferasirox were more likely to develop renal tubular dysfunction (OR 35.3, p=0.009), hypokalaemia (OR 23.2, p=0.015), hypophosphataemia (OR 57.0, p=0.001), hypocalcaemia (OR 23.2, p=0.015), and Fanconi syndrome (OR 15.6, p=0.004). Cumulative incidence of renal tubular dysfunction was estimated to be 89% at 6 years of deferasirox therapy. These effects were reversible with suspension or dose reduction of deferasirox. Vigilant monitoring of renal tubular dysfunction and serum electrolyte is recommended in patients who receive deferasirox.
DescriptionOral Presentation
This journal issue (pp. 192-206) entitled: Proceedings of Congress: Joint Annual Scientific Meeting 2014: The Hong Kong Paediatric Society and Hong Kong Paediatric Nurses Association 15 June, 2014
Open Access Journal
Persistent Identifierhttp://hdl.handle.net/10722/209588
ISSN
2015 Impact Factor: 0.194
2015 SCImago Journal Rankings: 0.123

 

DC FieldValueLanguage
dc.contributor.authorDee, CMA-
dc.contributor.authorCheuk, DKL-
dc.contributor.authorHa, SY-
dc.contributor.authorChiang, AKS-
dc.contributor.authorChan, GCF-
dc.date.accessioned2015-05-05T02:13:20Z-
dc.date.available2015-05-05T02:13:20Z-
dc.date.issued2014-
dc.identifier.citationThe 2014 Joint Annual Scientific Meeting of the Hong Kong Paediatric Society and Hong Kong Paediatric Nurses Association, Hong Kong, 15 June 2014. In Hong Kong Journal of Paediatrics, 2014, v. 19 n. 3, p. 193-
dc.identifier.issn1013-9923-
dc.identifier.urihttp://hdl.handle.net/10722/209588-
dc.descriptionOral Presentation-
dc.descriptionThis journal issue (pp. 192-206) entitled: Proceedings of Congress: Joint Annual Scientific Meeting 2014: The Hong Kong Paediatric Society and Hong Kong Paediatric Nurses Association 15 June, 2014-
dc.descriptionOpen Access Journal-
dc.description.abstractRenal tubular dysfunction has been reported in patients on deferasirox therapy but no systematic study has been performed. This study aimed to determine the cumulative incidence of renal tubular dysfunction and serum electrolyte imbalances among children and young adults with transfusion-dependent beta-thalassaemia on deferasirox and study their intermediate term outcomes. Mean age was 15.89 years (range: 2.6-24.10 years). Nine (50.0%) patients were on deferasirox, three (16.7%) were on deferoxamine, two (11.1%) were on deferiprone, and four (22.2%) were on combination deferiprone and deferoxamine. Twelve (66.7%) patients had renal tubular dysfunction, defined by elevated urine -2 microglobulin, of whom nine were on deferasirox. Eight patients (44.4%) had concomitant serum electrolyte imbalance, all of whom were on deferasirox. Compared to those on other chelation regimens, patients on deferasirox were more likely to develop renal tubular dysfunction (OR 35.3, p=0.009), hypokalaemia (OR 23.2, p=0.015), hypophosphataemia (OR 57.0, p=0.001), hypocalcaemia (OR 23.2, p=0.015), and Fanconi syndrome (OR 15.6, p=0.004). Cumulative incidence of renal tubular dysfunction was estimated to be 89% at 6 years of deferasirox therapy. These effects were reversible with suspension or dose reduction of deferasirox. Vigilant monitoring of renal tubular dysfunction and serum electrolyte is recommended in patients who receive deferasirox.-
dc.languageeng-
dc.publisherMedcom Limited. The Journal's web site is located at http://www.hkjpaed.org/index.asp-
dc.relation.ispartofHong Kong Journal of Paediatrics (New series)-
dc.subjectPediatrics-
dc.titleIncidence of deferasirox-associated renal tubular dysfunction in children and young adults with beta-thalassemia-
dc.typeConference_Paper-
dc.identifier.emailCheuk, DKL: cheukkld@hku.hk-
dc.identifier.emailHa, SY: syha@hku.hk-
dc.identifier.emailChiang, AKS: chiangak@hku.hk-
dc.identifier.emailChan, GCF: gcfchan@hku.hk-
dc.identifier.authorityChiang, AKS=rp00403-
dc.identifier.authorityChan, GCF=rp00431-
dc.identifier.hkuros243057-
dc.identifier.volume19-
dc.identifier.issue3-
dc.identifier.spage193-
dc.identifier.epage193-
dc.publisher.placeHong Kong-

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats